However, as PAB's product PAT-SM6 binds to over 90% of tumours...

However, as PAB's product PAT-SM6 binds to over 90% of tumours regardless of type and the successful phase 1/2a data is only of one condition, PAT-SM6 has greater potential than Elotuzumab.



2.

About PAT-SM6:

2.1

Potent anti-cancer properties in a large number of laboratory and animal studies.

2.2

Screened against more than 200 tumours from individual patients with various cancers, binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage.

2.3

Binds to a form of Glucose-regulated protein 78 (GRP78), which is expressed on the surface of cancer cells but not detected on the surface of healthy cells.

2.4

Once bound, the PAT-SM6/GRP78 complex is then internalised into cancer cells inducing apoptosis and cell death.

2.5

As a result, GRP78 expression has been correlated with an adverse prognosis in melanoma, breast, lung, gastric, hepatocellular and prostate cancer, and drug resistance in breast cancer.




3. safety proven and efficacy shown, multiple cancer targets, multiple revenue streams. Now for the Business Development people to capitalize. Further announcements impending?